Check out this infographic breakdown of the company’s first-quarter 2019 performance, with key highlights from its consumer, pharmaceutical and medical devices businesses.
We retrace the 22-year journey it took to bring a potentially life-changing treatment for an aggressive form of the disease to patients who may benefit most.
Up to 70% of nurses and nearly 55% of physicians report symptoms of burnout, which costs workplaces millions of dollars a year due to lost productivity and employee turnover and absenteeism—and impacts patient quality of care. But the CareAdvantage program is poised to help.
The innovative contact lenses change from clear to dark in less than a minute, helping your eyes adjust to fluctuating light conditions, while also blocking out harmful UV rays. A scientist explains how it all works.
Lisa Deck was just 21 when she had her first stroke. She would go on to have three more, as well as face a rare diagnosis of moyamoya disease. She shares her incredible story of survival and living with a chronic illness.
A new World Health Organization prequalification for mebendazole means the company can reach even more young people with intestinal worm infections around the globe.
The company just released its third annual report and leaders from across Janssen share some top takeaways, including a new initiative to include the list price and potential out-of-pocket costs for its most frequently prescribed medicine.
This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue